Damora Therapeutics

Damora Therapeutics is a private biotechnology company developing monoclonal antibody therapies for rare blood cancers. The company focuses on myeloproliferative neoplasms (MPN), including conditions such as essential thrombocythemia (ET) and myelofibrosis (MF), which are often caused by mutations in calreticulin (mutCALR) within patients.